Agenus

Deal terminate tear up end deal scrap
Biotech

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

UroGen is handing back an anti-CTLA-4 antibody after concluding that phase 1 data for the bladder cancer drug didn’t warrant further development.
James Waldron Nov 6, 2025 10:00am
Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

BMS oncology head swings to Syndax—Chutes & Ladders

May 16, 2025 8:30am
Deal terminate tear up end deal scrap

Incyte exits cancer pact, leaving Agenus weighing its options

Feb 11, 2025 7:55am
peeling an orange

Bristol Myers culls cell therapy deals with 2 biotechs

Dec 16, 2024 11:19am
Deal terminate tear up end deal scrap

BMS ditches TIGIT, ending $200M bet on Agenus bispecific

Aug 5, 2024 9:17am
Image of a neon sign with the word no lit up next to an unlit yes

FDA wrecks Agenus’ accelerated approval plan

Jul 18, 2024 8:01am